Market Closed -
Bombay S.E.
06:00:50 2024-04-26 am EDT
5-day change
1st Jan Change
2,690
INR
-0.07%
+6.05%
+16.72%
Sales 2024 *
108B
1.3B
Sales 2025 *
122B
1.46B
Capitalization
911B
10.92B
Net income 2024 *
16.43B
197M
Net income 2025 *
20.55B
247M
EV / Sales 2024 *
8.76
x
Net Debt
2024
*
37.16B
446M
Net Debt
2025
*
25.26B
303M
EV / Sales 2025 *
7.67
x P/E ratio 2024 *
56.1
x
P/E ratio 2025 *
44.3
x
Employees
13,247
Yield 2024 *
0.8%
Yield 2025 *
0.9%
Free-Float
28.64%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60
Apr. 08
CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024
Apr. 01
CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director
Feb. 29
CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy
Feb. 08
MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents
Feb. 05
MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy
Feb. 05
MT
Torrent Pharmaceuticals Posts Gains in Fiscal Q3 Consolidated Net Profit
Feb. 04
MT
Torrent Pharmaceuticals' Consolidated Profit in Fiscal Q3
Feb. 02
MT
Transcript : Torrent Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 02, 2024
Feb. 02
India's Torrent Pharma posts higher Q3 profit on strong domestic demand
Feb. 02
RE
Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024
Feb. 02
CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Feb. 02
CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO
Jan. 23
RE
Torrent Pharmaceuticals Forms New Wholly-Owned Arm in Colombia
Jan. 04
MT
Torrent Pharmaceuticals' Oral Oncology Plant Gets Fives Observations from US FDA
Dec. 11
MT
More news
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy
Feb. 08
MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy
Feb. 05
MT
Nomura Adjusts Torrent Pharmaceuticals Price Target to INR2,156 From INR2,199, Keeps at Buy
23-10-25
MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,040 From INR1,950, Keeps at Hold
23-10-24
MT
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,199 From INR1,838, Keeps at Buy
23-09-07
MT
More recommendations
1 day -0.07%
1 week +6.05%
Current month +3.43%
1 month +4.70%
3 months +8.74%
6 months +42.26%
Current year +16.72%
More quotes
Managers
Title Age Since
Director of Finance/CFO
-
-
Compliance Officer
-
22-07-31
Chief Operating Officer
47
19-07-31
Members of the board
Title Age Since
Director/Board Member
70
82-06-22
Chairman
60
85-12-31
Director/Board Member
57
19-03-06
More insiders
Date
Price
Change
Volume
24-04-26
2,690
-0.07%
4,270
24-04-25
2,692
+0.28%
1,149
24-04-24
2,685
+1.85%
4,480
24-04-23
2,636
+1.76%
1,466
24-04-22
2,591
+2.12%
4,372
Delayed Quote
Bombay S.E., April 26, 2024 at 06:00 am EDT
More quotes
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
More about the company
Last Close Price
2,690
INR
Average target price
2,729
INR
Spread / Average Target
+1.43%
Consensus
1st Jan change
Capi.
+16.72% 10.92B +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1